Skip to content

Zymeworks ZYME Depreciation

Depreciation at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Charles River Laboratories logo
Charles River LaboratoriesCRL
Summit Therapeutics logo
Summit TherapeuticsSMMT
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's depreciation?
Zymeworks (ZYME) reported depreciation of $963K in Q1 2026.
How has Zymeworks's depreciation changed year-over-year?
Zymeworks's depreciation decreased by 1.8% year-over-year, from $981K to $963K.
What is the long-term trend for Zymeworks's depreciation?
Over 4 years (2021 to 2025), Zymeworks's depreciation has grown at a -0.5% compound annual growth rate (CAGR), from $3.74M to $3.67M.